Pelacarsen Lowered the Biomarker. It Did Not Save Lives. Now What?

Pelacarsen Lowered the Biomarker. It Did Not Save Lives. Now What?

Why Pharma’s AI Future Depends on Standardization First

The Dystrophin Standard: How a 1% Biomarker Signal Became a $967 Million Accelerated Approval Precedent

The Dystrophin Standard: How a 1% Biomarker Signal Became a $967 Million Accelerated Approval Precedent

Icotrokinra's NEJM Data Reveals the Quiet Shift in How UC Trials Get Designed and Approved

Icotrokinra’s NEJM Data Reveals the Quiet Shift in How UC Trials Get Designed and Approved

Editor's Choice

GLP-1 Agonists Cut Psychiatric Hospitalizations in Schizophrenia. The Field Isn't Ready to Study Why.
Psych Pulse

GLP-1 Drugs Linked to Fewer Psychiatric Hospitalizations in People With Schizophrenia and Type 2 Diabetes

The Psilocybin Layer 5 Finding Changes How I Think About What We're Actually Dosing For
Psych Pulse

The Psilocybin Layer 5 Finding Changes How I Think About What We’re Actually Dosing For

When Payer Status Becomes a Protocol Variable: What the Medicare Advantage Transplant Gap Means for ESKD Trial Enrollment
Clinical Trial Ops Brief

When Payer Status Becomes a Protocol Variable: What the Medicare Advantage Transplant Gap Means for ESKD Trial Enrollment

CLINICAST

Start typing and press Enter to search